Interleukin-17A Antagonist

Interleukin-17A Antagonists

Psoriasis

<section class="Section" data-sectioncode="34089-3"><a name="s53"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule.</p><p>TALTZ injection is a sterile, preservative free, clear and colorless to slightly yellow solution, for subcutaneous use available as 80 mg of ixekizumab in a 1 mL single-dose prefilled autoinjector or a single-dose prefilled syringe. The prefilled autoinjector and prefilled syringe each contain a 1 mL glass syringe with a fixed 27 gauge ½ inch needle. The TALTZ 80 mg prefilled autoinjector and prefilled syringe are manufactured to deliver 80 mg of ixekizumab.</p><p>Each mL is composed of ixekizumab (80 mg); Polysorbate 80, USP (0.3 mg); Sucrose, USP (80 mg); and Water for Injection, USP. Sodium Hydroxide, USP-NF, may have been added to adjust pH. The TALTZ solution has a pH of 5.2 –  6.2.</p></section>

TALTZ

1 ML ixekizumab 80 MG/ML Auto-Injector

1 ML ixekizumab 80 MG/ML Auto-Injector [Taltz]

1 ML ixekizumab 80 MG/ML Prefilled Syringe

1 ML ixekizumab 80 MG/ML Prefilled Syringe [Taltz]

Taltz

ixekizumab

Ankylosing Spondylitis

Psoriatic Arthritis

<section class="Section" data-sectioncode="34089-3"><a name="section-10"></a><p></p><h1>11     DESCRIPTION</h1><p class="First">Secukinumab, a recombinant human monoclonal IgG1/κ antibody, is an interleukin-17A antagonist. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Secukinumab has a molecular mass of approximately 151 kDa; both heavy chains of secukinumab contain oligosaccharide chains.</p><p><span class="Underline">COSENTYX Injection</span></p><p>COSENTYX injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for subcutaneous use. COSENTYX is supplied in a single-dose Sensoready pen with a 27-gauge fixed ½-inch needle, or a single-dose prefilled syringe with a 27-gauge fixed ½-inch needle. The removable cap of the COSENTYX Sensoready pen or prefilled syringe contains natural rubber latex.</p><p>Each COSENTYX Sensoready pen or prefilled syringe contains 150 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (3.103 mg), L-methionine (0.746 mg), polysorbate 80 (0.2 mg), trehalose dihydrate (75.67 mg), and Sterile Water for Injection, USP, at pH of 5.8.</p><p>Each COSENTYX 75 mg/0.5 mL prefilled syringe contains 75 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (1.552 mg), L-methionine (0.373 mg), polysorbate 80 (0.1 mg), trehalose dihydrate (37.83 mg), and Sterile Water for Injection, USP, at pH of 5.8. </p><p><span class="Underline">COSENTYX for Injection</span></p><p>COSENTYX for injection is supplied as a sterile, preservative free, white to slightly yellow, lyophilized powder in single-dose vials for subcutaneous use after reconstitution. Each COSENTYX vial contains 150 mg of secukinumab formulated in L-histidine/histidine hydrochloride monohydrate (4.656 mg), polysorbate 80 (0.6 mg), and sucrose (92.43 mg). Following reconstitution with 1 mL Sterile Water for Injection, USP, the resulting pH is approximately 5.8.</p></section>

COSENTYX

0.5 ML secukinumab 150 MG/ML Prefilled Syringe

0.5 ML secukinumab 150 MG/ML Prefilled Syringe [Cosentyx]

1 ML secukinumab 150 MG/ML Auto-Injector

1 ML secukinumab 150 MG/ML Auto-Injector [Cosentyx]

1 ML secukinumab 150 MG/ML Prefilled Syringe

1 ML secukinumab 150 MG/ML Prefilled Syringe [Cosentyx]

Cosentyx

secukinumab

Taltz, a monoclonal antibody, has anti-inflammatory properties and can potentially alleviate symptoms of psoriasis, psoriatic arthritis, or ankylosing spondylitis. Its administration involves subcutaneous injection, and the most common side effects include injection site reactions and an elevated susceptibility to infections.

Taltz is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondylarthritis. 


Report Adverse Event

Prescribing Information

Medication Guide

Submit MSL Request 

Pharmacy List 

Reimbursement Information

Coverage Authorization Request

Coverage Authorization Appeals

Letter of Medical Necessity 

Taltz Together Enrollment & Prescription Form - Adult Dermatology

Taltz Together Enrollment & Prescription Form - Pediatric Dermatology

Taltz Together Enrollment & Prescription Form - Adult Rheumatology

Enroll in Patient Savings Program

Lilly Cares Patient Assistance Program Eligibility Check 

Mechanism of Action (MOA)

Efficacy: Plaque Psoriasis 

Efficacy (Head-to-Head Data): Plaque Psoriasis 

Efficacy (Challenging Body Areas): Plaque Psoriasis

Efficacy & Safety (Pediatric Data): Plaque Psoriasis 

Safety Profile: Plaque Psoriasis 

Dosing (Adult & Pediatric): Plaque Psoriasis 

Efficacy: Psoriatic Arthritis 

Efficacy (H2H vs Humira): Psoriatic Arthritis 

Safety Profile: Psoriatic Arthritis 

Efficacy: Ankylosing Spondylitis (AS)

Efficacy: Non-radiographic Axial Spondyloarthritis (nr-axSpA)

Safety Profile: Ankylosing Spondylitis (AS) & Non-radiographic Axial Spondyloarthritis (nr-axSpA)

Dosing: Psoriatic Arthritis, AS & nr-axSpA

About Taltz: Plaque Psoriasis 

Patient Stories: Plaque Psoriasis

Before & After: Plaque Psoriasis

Genital Plaque Psoriasis 

About Taltz (Pediatric): Plaque Psoriasis

Before & After (Pediatric): Plaque Psoriasis

About Taltz: Psoriatic Arthritis 

Patient Stories: Psoriatic Arthritis

About Taltz: Ankylosing Spondylitis (AS) & Non-radiographic Axial Spondyloarthritis (nr-axSpA)

Taking Taltz: Plaque Psoriasis

Taking Taltz (Pediatrics): Plaque Psoriasis 

Taking Taltz: Psoriatic Arthritis 

Taking Taltz: Ankylosing Spondylitis (AS)

Taking Taltz: Non-radiographic Axial Spondyloarthritis (nr-axSpA)

App Download 

Taltz Cost Information

Sharps Disposal

Taltz Together Program 

Instructions For Use: Psoriasis 

Instructions For Use: Psoriatic Arthritis 

Instructions For Use: Ankylosing Spondylitis 

Instructions For Use: Non-radiographic Axial Spondyloarthritis (nr-axSpA)

Cosentyx is a monoclonal antibody treatment option for several conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and others. Following the initial loading dose, subcutaneous injection of Cosentyx is required every four weeks, but patients can typically be taught to self-administer using the Sensoready pen or prefilled syringe. Nasopharyngitis and an elevated risk of infection are the most frequently reported side effects.

Cosentyx is FDA approved for the following indications: Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondylarthritis, and Enthesitis-related Arthritis. 


Report Adverse Event 

Medication Guide 

Online Sample Form 

Reimbursement Information 

Billing & Coding Guide 

Consentyx Connect Start Form 

Cosentyx Connect Start Form - Spanish

Coverage Authorization Request: Plaque Psoriasis 

Coverage Authorization Appeals: Plaque Psoriasis

Letter of Medical Necessity: Plaque Psoriasis

Formulary Exception Request Letter: Plaque Psoriasis 

Tiering Exception Request Letter: Plaque Psoriasis

Coverage Authorization Request: Psoriatic Arthritis

Coverage Authorization Appeals: Psoriatic Arthritis 

Letter of Medical Necessity: Psoriatic Arthritis 

Formulary Exception Request Letter: Psoriatic Arthritis 

Tiering Exception Request Letter: Psoriatic Arthritis 

Dosage Appeals Letter: Psoriatic Arthritis 

Coverage Authorization Request: Ankylosing Spondylitis 

Coverage Authorization Appeals: Ankylosing Spondylitis 

Letter of Medical Necessity: Ankylosing Spondylitis 

Formulary Exception Request Letter: Ankylosing Spondylitis 

Tiering Exception Request Letter: Ankylosing Spondylitis 

Dosage Appeals Letter: Ankylosing Spondylitis 

Coverage Authorization Request: nr-axSpA

Coverage Authorization Appeals:  nr-axSpA

Letter of Medical Necessity:  nr-axSpA

Formulary Exception Request Letter:  nr-axSpA

Tiering Exception Request Letter: nr-axSpA

Dosage Appeals Letter:  nr-axSpA

Coverage Authorization Request: JPsa & ERA

Coverage Authorization Appeals: JPsa & ERA

Letter of Medical Necessity: JPsa & ERA

Formulary Exception Request Letter: JPsa & ERA

Tiering Exception Request Letter: JPsa & ERA

Dosage Appeals Letter: JPsa & ERA

Coverage Authorization Request: PsA with PsO

Coverage Authorization Appeals: PsA with PsO

Letter of Medical Necessity : PsA with PsO

Formulary Exception Request Letter: PsA with PsO

Tiering Exception Request Letter: PsA with PsO

Medical Exception Request Letter 

Efficacy & Safety Profile: Plaque Psoriasis (Pediatric)

Efficacy (Clinical Manifestations): Psoriatic Arthritis 

Efficacy (Radiographic Progression): Psoriatic Arthritis 

Efficacy (MDA): Psoriatic Arthritis 

Efficacy (HAQ-DI): Psoriatic Arthritis 

Efficacy (Fatigue): Psoriatic Arthritis 

Efficacy (Disease Hallmarks): Ankylosing Spondylitis

Efficacy (hsCRP): Ankylosing Spondylitis 

Efficacy (ASDAS-CRP): Ankylosing Spondylitis 

Safety Profile: Ankylosing Spondylitis 

Efficacy (Disease Hallmarks): nr-axSpA

Efficacy (SI Joint Edema): nr-axSpA

Efficacy (hsCRP): nr-axSpA

Safety Profile: nr-axSpA

Efficacy (Time to Flare): JPsA

Efficacy (JIA ACR): JPsA

Efficacy (Enthesitis/Dacylitis): JPsA

Efficacy (Disease Activity): JPsA

Efficacy (Skin Clearance): JPsA

Safety Profile: JPsA/ERA

Efficacy (Time to Flare): ERA

Efficacy (JIA ACR): ERA

Efficacy (Enthesistis/Dacylitis): ERA

Efficacy (Disease Activity): ERA

Dosing: All Indications

Enroll in Patient Savings Program 

Enroll in Bridge Program 

Cosentyx Patient Assistance Program Income Requirements 

Novartis Patient Assistance Foundation Application - English

Novartis Patient Assitance Foundation Application - Spanish 

Cosentyx Connect Support Program

Sharps Container 

About Cosentyx: Plaque Psoriasis 

FAQs: Plaque Psoriasis

Patient Stories: Plaque Psoriasis 

Twill Care App: Plaque Psoriasis

Taking Cosentyx: Plaque Psoriasis

Side Effects

Doctor Discussion Guide: PsA, PsO, AS, nr-axSpA

About Cosentyx: Psoriatic Arthritis 

FAQs: Psoriatic Arthritis 

Patient Stories: Psoriatic Arthritis 

Patient Resources: Psoriatic Arthritis 

Taking Cosentyx: Psoriatic Arthritis 

About Cosentyx: Ankylosing Spondylitis

Patient Stories: Ankylosing Spondylitis

FAQs: Ankylosing Spondylitis 

Taking Cosentyx: Ankylosing Spondylitis 

About Cosentyx: nr-axSpA

FAQs: nr-axSpA 

Taking Cosentyx: nr-axSpA

About Cosentyx: Pediatric Psoriasis 

Skyrizi

Stelara

Tremfya

Taltz®(ixekizumab)	Cosentyx®(secukinumab)

Prescription Only Taltz, a monoclonal antibody, has anti-inflammatory properties and can potentially alleviate symptoms of psoriasis, psoriatic arthritis, or ankylosing spondylitis. Its...	Prescription Only Cosentyx is a monoclonal antibody treatment option for several conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and others. Following the...
Dosage & Administration
Administration
Subcutaneous Injection. Learn more.	Subcutaneous Injection. Learn more.
Dosing
Recommended dosage is 80 mg by subcutaneous injection every 4 weeks.. Learn more.	* With a loading dosage: 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. * Without a loading dosage: 150 mg every 4 weeks.. Learn more.
Latin Shorthand
80mg SC inj. Q4W. Learn more.	W/ Loading Dose: 150mg Wks 0,1,2,3,4, then q4wks. W/o Loading Dose: 150mg q4wks.. Learn more.
Adverse Reactions
Most common (≥1%) adverse reactions associated with TALTZ treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.. Learn more.	Most common adverse reactions (> 1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection. . Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
$5. Learn more.	$0. Learn more.
Annual Cap
$9,100. Learn more.	Learn more.
Assistance Expiration
12/31/2025 or 36 months from qualification, whichever comes first (with prior authorization and appeal process as required). Learn more.	Learn more.
Generics
No lower-cost generic available	No lower-cost generic available

Taltz® Alternatives